Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lorlatinib Continuation Study
Sponsor: Pfizer
Summary
The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention
Official title: LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
76
Start Date
2021-12-28
Completion Date
2026-12-28
Last Updated
2025-12-17
Healthy Volunteers
No
Conditions
Interventions
Lorlatinib
ALK-positive NSCL treatment
Locations (27)
Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
The First affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Hunan Provincial Tumor Hospital
Changsha, Hunan, China
General Hospital of Eastern Theater Command
Nanjing, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
The first hospital of jilin university
Changchun, Jilin, China
Sir Run Shaw Hospital
Hangzhou, Qiantang District, China
The Second Affiliated Hospital of PLA Air Force Medical University
Xi'an, Shaanxi, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Sichuan Cancer hospital
Chengdu, Sichuan, China
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Zhejiang University College of Medicine
Hangzhou, Zhejiang, China
Fudan University Shanghai Cancer Center
Shanghai, China
CHU de Rennes - Hôpital Pontchaillou
Rennes, France
Institut Gustave Roussy
Villejuif, France
Healthcare Global Enterprises
Bengaluru, Karnataka, India
Bhaktivedanta Hospital & Research Institute
Thane, Maharashtra, India
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
National University Hospital
Singapore, Singapore
National Cancer Centre Singapore
Singapore, Singapore
Hospital Universitari Vall d'Hebron
Barcelona, Spain
National Taiwan University Hospital
Taipei, Taiwan